LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Rating of “Moderate Buy” from Analysts

Posted by Francis Steltz on Aug 1st, 2026

LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the nine research firms that are covering the company, MarketBeat reports. Four analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $112.60.

Several research analysts have weighed in on LMAT shares. Zacks Research cut LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Weiss Ratings cut shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, June 30th. Barrington Research restated an “outperform” rating and issued a $120.00 price target on shares of LeMaitre Vascular in a research note on Wednesday, June 3rd. Wall Street Zen lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Citigroup reiterated a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st.

Get Our Latest Report on LMAT

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT opened at $101.32 on Friday. The firm has a market cap of $2.32 billion, a P/E ratio of 37.39, a price-to-earnings-growth ratio of 2.84 and a beta of 0.52. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42. LeMaitre Vascular has a 1-year low of $79.00 and a 1-year high of $118.01. The business’s 50 day moving average is $97.15 and its 200-day moving average is $99.65.

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.02. The business had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The firm’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period last year, the firm posted $0.48 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities research analysts predict that LeMaitre Vascular will post 3 earnings per share for the current year.

Insider Transactions at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,928 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $107.00, for a total transaction of $313,296.00. Following the sale, the insider owned 3,749 shares of the company’s stock, valued at $401,143. This represents a 43.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO George W. Lemaitre sold 27,881 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the transaction, the chief executive officer owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. This trade represents a 1.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 54,453 shares of company stock valued at $5,906,174. 7.40% of the stock is currently owned by company insiders.

Institutional Trading of LeMaitre Vascular

A number of institutional investors have recently modified their holdings of the stock. Handelsbanken Fonder AB acquired a new stake in shares of LeMaitre Vascular during the 2nd quarter worth $806,000. Contravisory Investment Management Inc. bought a new position in shares of LeMaitre Vascular in the second quarter worth $233,000. Pacer Advisors Inc. raised its stake in LeMaitre Vascular by 45.7% in the first quarter. Pacer Advisors Inc. now owns 2,172 shares of the medical instruments supplier’s stock valued at $237,000 after purchasing an additional 681 shares in the last quarter. Glenmede Trust Co. NA raised its stake in LeMaitre Vascular by 14.8% in the first quarter. Glenmede Trust Co. NA now owns 9,547 shares of the medical instruments supplier’s stock valued at $1,042,000 after purchasing an additional 1,234 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in LeMaitre Vascular by 39.0% during the first quarter. Bank of America Corp DE now owns 180,095 shares of the medical instruments supplier’s stock worth $19,661,000 after purchasing an additional 50,497 shares during the period. 84.64% of the stock is currently owned by institutional investors.

About LeMaitre Vascular

(Get Free Report)

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.